DV
Dividend Vision

ACOG Stock — Alpha Cognition Inc

Alpha Cognition Inc (ACOG)

Updated October 16, 2026.

ACOG is a Stock. Total return is -2.5% over the past 1.9 years, 32.9 points behind SPY at 30.4%.

Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, including an oral tablet formulation of ZUNVEYL for Alzheimer's disease in commercial development and several pre-clinical programs targeting cognitive impairment and conditions such as ALS and spinal muscular atrophy. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage biotech development with a focus on neurological disease treatment.

ACOG performance versus SPY

Price and return data through 2026-10-16.

Total return is -2.5% over the past 1.9 years, 32.9 points behind SPY at 30.4%. Over the past year its total return — price change plus distributions reinvested — is 16.0%. Its deepest 1-year drawdown was 36.9%.

WindowTotal returnCAGR
1M-2.5%—
3M-1.9%—
6M23.2%—
YTD26.0%—
1Y16.0%—
Since inception (1.9 years)-2.5%-1.30%

ACOG key facts

Asset type
Stock
Asset class
Equity
Inception date
11/11/2024
Distribution frequency
None
Last close
$8.19 (as of 2026-10-16)
Market cap
$178,360,739
Average volume
70408.0
Beta
2.228
Payout ratio
0.0%
Forward P/E
26.8817
EPS
$-1.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACOG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 36.9%.

Who may consider ACOG — and who may not

It is a weaker fit for investors who need monthly cash flow (ACOG does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACOG

Tagged: Healthcare.

Frequently asked questions

Does ACOG pay monthly?

No. ACOG does not currently distribute.

When does ACOG pay a dividend?

ACOG does not currently distribute.

How has ACOG performed?

Total return is -2.5% over the past 1.9 years, 32.9 points behind SPY at 30.4%. Over the past year its total return — price change plus distributions reinvested — is 16.0%. Its deepest 1-year drawdown was 36.9%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.